Get started
Co-Diagnostics, Inc.Co-Diagnostics, Inc.Co-Diagnostics, Inc.

Co-Diagnostics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CODX chart


Full chart

CODX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪24.52 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.3518 USD
Net income (FY)
‪−35.33 M‬ USD
Revenue (FY)
‪991.47 K‬ USD
Shares float
‪29.46 M‬
Beta (1Y)
1.57

Employees


Employees (FY)
155
Change (1Y)
+10 +6.90%
Revenue / Employee (1Y)
‪6.40 K‬ USD
Net income / Employee (1Y)
‪−227.95 K‬ USD

About Co-Diagnostics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Dwight Howard Egan
Website
codiagnostics.com
Headquarters
Salt Lake City
Founded
2013
FIGI
BBG004HTR2D1
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CODX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CODX is 0.7680 USD — it has increased by 5.34% in the past 24 hours. Watch Co-Diagnostics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Co-Diagnostics, Inc. stocks are traded under the ticker CODX.
CODX stock has fallen by −2.78% compared to the previous week, the month change is a −27.55% fall, over the last year Co-Diagnostics, Inc. has showed a −33.79% decrease.
We've gathered analysts' opinions on Co-Diagnostics, Inc. future price: according to them, CODX price has a max estimate of 1.50 USD and a min estimate of 1.50 USD. Watch CODX chart and read a more detailed Co-Diagnostics, Inc. stock forecast: see what analysts think of Co-Diagnostics, Inc. and suggest that you do with its stocks.
CODX reached its all-time high on Aug 3, 2020 with the price of 30.9900 USD, and its all-time low was 0.6940 USD and was reached on Jun 5, 2019. View more price dynamics on CODX chart.
See other stocks reaching their highest and lowest prices.
CODX stock is 9.14% volatile and has beta coefficient of 1.57. Track Co-Diagnostics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Co-Diagnostics, Inc. there?
Today Co-Diagnostics, Inc. has the market capitalization of ‪24.52 M‬, it has decreased by −4.07% over the last week.
Yes, you can track Co-Diagnostics, Inc. financials in yearly and quarterly reports right on TradingView.
Co-Diagnostics, Inc. is going to release the next earnings report on Apr 8, 2025. Keep track of upcoming events with our Earnings Calendar.
CODX earnings for the last quarter are −0.32 USD per share, whereas the estimation was −0.33 USD resulting in a 3.03% surprise. The estimated earnings for the next quarter are −0.34 USD per share. See more details about Co-Diagnostics, Inc. earnings.
Co-Diagnostics, Inc. revenue for the last quarter amounts to ‪641.14 K‬ USD, despite the estimated figure of ‪375.00 K‬ USD. In the next quarter, revenue is expected to reach ‪375.00 K‬ USD.
CODX net income for the last quarter is ‪−9.70 M‬ USD, while the quarter before that showed ‪−7.60 M‬ USD of net income which accounts for −27.60% change. Track more Co-Diagnostics, Inc. financial stats to get the full picture.
No, CODX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 155.00 employees. See our rating of the largest employees — is Co-Diagnostics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Co-Diagnostics, Inc. EBITDA is ‪−41.81 M‬ USD, and current EBITDA margin is ‪−4.77 K‬%. See more stats in Co-Diagnostics, Inc. financial statements.
Like other stocks, CODX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Co-Diagnostics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Co-Diagnostics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Co-Diagnostics, Inc. stock shows the sell signal. See more of Co-Diagnostics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.